PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
H.R. 741, To amend the Federal Food, Drug, and Cosmetic Act to prohibit the marketing of authorized generic drugs: Provisions related to authorized generics H.R. 3261, Stop Online Piracy Act: Provisions related to anti-counterfeiting H.R. 3468, Counterfeit Drug Penalty Enhancement Act of 2011: Provisions related to anti-counterfeiting H.R. 3995, Protect Consumer Access to Generic Drugs Act: Provisions related to patent settlements H.R. 4216, Foreign Counterfeit Protection Act: Provisions related to anti-counterfeiting H.R. 6502, Life-Threatening Diseases Compassion through Combination Therapy Act: Provisions related to market exclusivity and expedited review H.R. 6621, a bill to make technical corrections to the America Invents Act H.R. 6654, Foreign Counterfeit Merchandise Prevention Act: Provisions related to trade enforcement S. 27, The Preserve Access to Affordable Generics Act: Provisions related to patent settlements S. 373, The Fair Prescription Drug Competition Act: Provisions related to authorized generics S. 968, Preventing Online Threats to Economic Creativity and Theft of Intellectual Property Act of 2011: Provisions related to anti-counterfeiting S. 1734, Generating Antibiotic Incentives Now Act of 2011: Provisions related to antibiotics and incentives S. 1882, Fair and Immediate Release of Generic Drugs Act: Provisions related to patent settlements S. 1886, Counterfeit Drug Penalty Enhancement Act of 2011: Provisions related to anti- counterfeiting S. 3486, Patent Law Treaties Implementation Act of 2012: Patent law treaties S. 3652, Patents for Humanity Program Improvements Act of 2012: Provisions related to transferability of PTO acceleration certificates International intellectual property issues Biopharmaceutical innovation policy issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL ANWAY | — |
| CHESTER (CHIP) DAVIS | — |
| LEO FARBER | — |
| ROBERT FILIPPONE | — |
| LEA FISHER | — |
| VALERIE HARDIN JEWETT | — |
| DAVID KORN | — |
| CARA MOON | — |
| JAMES M SPEARS | — |
| MATTHEW L SULKALA | — |
Health Issues HCR
H.R.1316, Stop Oxy Abuse Act of 2011: To limit the approval of any drug containing controlled-release oxycodone hydrochloride H.R. 1513, Great Ape Protection and Cost Savings Act of 2011: Provisions related to pre-clinical testing H.R. 2674, 340B Program Improvement Act: Provisions related to 340B H.R. 4132, FAST Act: Provisions related to accelerated approval and other FDA matters H.R. 4156, Expanding and Promoting Expertise in Rare Treatments Act of 2012: To strengthen the FDAs ability to seek advice from external experts regarding rare diseases H.R. 4209, Patients Access to Treatments Act: To limit cost-sharing requirements applicable to prescription drugs in a specialty drug tier H.R. 4274, To amend title IV of the Public Health Service Act and title V of the Federal Food, Drug, and Cosmetic Act to permanently extend the provisions of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act of 2003 H.R. 6288, Patient Choice Act: To permit provisional approval of fast track products H.R. 6342, Compassionate Freedom of Choice Act: Provisions related to access to investigational drugs or devices for terminally ill patients H.R. 6584, Verifying Authority and Legality In Drug Compounding Act: Provisions relating to drug compounding H.R. 6611, Patient Access to Drugs in Shortage Act of 2012: Promote public notification and provide incentives to reduce drug shortages S. 296, Preserving Access to Life-Saving Medications Act: Provisions related to prescription drug shortages S. 810, Great Ape Protection and Cost Savings Act of 2011: Provisions related to pre-clinical testing S. 1699, Prescription Drug Cost Reduction Act: Provisions related to 340B S. 2002, Online Pharmacy Safety Act: To improve the safety of Internet pharmacies S. 2113, Transforming the Regulatory Environment to Accelerate Access to Treatments (TREAT) Act: Provisions related to accelerated approval and other FDA matters S. 2236, Advancing Breakthrough Therapies for Patients Act of 2012: Provisions related to FDA regulation S.2281, Expanding and Promoting Expertise in Rare Treatments Act of 2012: To strengthen the FDAs ability to seek advice from external experts regarding rare diseases S. 3187, Food and Drug Administration Safety and Innovation Act: Provisions related to user fee reauthorization and FDA reform Implementation issues relating to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including PPACA; Standards Related to Essential Health Benefits, Actuarial Value, and Accreditation rulemaking Vaccine-related policy issues Comparative effectiveness policy issues General HHS and FDA related advocacy Biopharmaceutical innovation policy issues Pharmaceutical supply chain security issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL ANWAY | — |
| MAYA BERMINGHAM | — |
| RANDY BURKHOLDER | — |
| CHESTER (CHIP) DAVIS | — |
| ANDREA JEAN DOUGLAS | — |
| LEO FARBER | — |
| ROBERT FILIPPONE | — |
| LEA FISHER | — |
| JEFFREY FRANCER | — |
| SASCHA HAVERFIELD-GROSS | — |
| VALERIE HARDIN JEWETT | — |
| ANN KAPLAN | — |
| DAVID KORN | — |
| KIMBERLY LOVE | — |
| COLLEEN MALONEY | — |
| KENDRA MARTELLO | — |
| CARA MOON | — |
| LORI REILLY | — |
| JENNIFER ROMANS | — |
| NICK SHIPLEY New | Legislative Director - Rep. Jay Inslee |
| RICHARD SMITH | — |
| JAMES M SPEARS | — |
| MATTHEW L SULKALA | — |
Budget/Appropriations BUD
The Budget Control Act of 2011 (Public Law 112-25): Sequester implementation H.J. Res. 117, Continuing Appropriations Resolution, 2013: Provisions related to FDA funding, oversight, trade, prescription drug abuse, comparative effectiveness research, NIH funding, BARDA funding, PPACA implementation funding, 340B, IPAB, defense health accounts, biodefense funding/projects, and defense contracting
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL ANWAY | — |
| MAYA BERMINGHAM | — |
| RANDY BURKHOLDER | — |
| JOHN J CASTELLANI | — |
| CHESTER (CHIP) DAVIS | — |
| ANDREA JEAN DOUGLAS | — |
| LEO FARBER | — |
| ROBERT FILIPPONE | — |
| LEA FISHER | — |
| JEFFREY FRANCER | — |
| SASCHA HAVERFIELD-GROSS | — |
| VALERIE HARDIN JEWETT | — |
| COLLEEN MALONEY | — |
| LORI REILLY | — |
| JENNIFER ROMANS | — |
| NICK SHIPLEY New | Legislative Director - Rep. Jay Inslee |
| RICHARD SMITH | — |
| JAMES M SPEARS | — |
| MATTHEW L SULKALA | — |
Trade (domestic/foreign) TRD
H.R. 6083, Federal Agriculture Reform and Risk Management Act of 2012: Provisions related to WTO Brazil cotton dispute H.R. 6156, Russia and Moldova Jackson-Vanik Repeal and Sergei Magnitsky Rule of Law Accountability Act of 2012: Trade relations provisions S. 3240, Agriculture Reform, Food, and Jobs Act of 2012: Provisions related to WTO Brazil cotton dispute S. 3285, A bill to authorize the extension of nondiscriminatory treatment (normal trade relations treatment) to products of the Russian Federation Korea Free Trade Agreement: Implementation issues related to intellectual property, market access and public health Colombia Free Trade Agreement: Implementation issues related to intellectual property, market access and public health Trans-Pacific Strategic Economic Partnership Agreement (TPP): Provisions related to intellectual property, market access and public health issues Mexico and Canada IP and market access issues in context of invitation to join TPP negotiations Turkey Market Access Issues India innovation and market access issues EU/US trade liberalizing agreement Issues related to Special 301 and National Trade Estimate (NTE) submissions Preference Programs International market access and intellectual property issues Anti-counterfeiting policy issues Biopharmaceutical innovation policy issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN J CASTELLANI | — |
| CHESTER (CHIP) DAVIS | — |
| LEO FARBER | — |
| ROBERT FILIPPONE | — |
| DAVID KORN | — |
| ANNE PRITCHETT | — |
| JAMES M SPEARS | — |
Medicare/Medicaid MMM
H.R. 5, Protecting Access to Healthcare Act: Provisions related to Independent Payment Advisory Board (IPAB) H.R. 8, American Taxpayer Relief Act of 2012: Medicare and tax related provisions H.R. 452, Medicare Decisions Accountability Act of 2011: Provisions related to Independent Payment Advisory Board (IPAB) H.R. 999, Medicare Prescription Drug Savings and Choice Act of 2011: Provisions related to Part D issues H.R. 2190 Medicare Drug Savings Act of 2011: Provisions related to Part D issues H.R. 4209, Patients Access to Treatments Act of 2012: Provisions related to capping specialty tier drugs and no cost-sharing above the non-preferred brand tier S. 365, Budget Control Act of 2011: Deficit reduction issues related to Medicare/Medicaid S. 668, Health Care Bureaucrats Elimination Act: Provisions related to Independent Payment Advisory Board (IPAB) S. 1206, Medicare Prescription Drug Savings Act of 2011: Provisions related to Part D issues S. 1699, Prescription Drug Cost Reduction Act: Provisions related to Medicare Part B, 340B, least costly alternative, and other provisions Deficit reduction policy issues Medicaid Program, Covered Outpatient Drugs rulemaking Dual eligibles coordination policy issues Implementation issues relating to the Physician Payment Sunshine Act, including Medicare, Medicaid, Childrens Health Insurance Programs; Transparency Reports and Reporting of Physician Ownership or Investment Interests rulemaking
| Lobbyist | Covered position, as disclosed |
|---|---|
| MICHAEL ANWAY | — |
| MAYA BERMINGHAM | — |
| RANDY BURKHOLDER | — |
| JOHN J CASTELLANI | — |
| CHESTER (CHIP) DAVIS | — |
| ANDREA JEAN DOUGLAS | — |
| ROBERT FILIPPONE | — |
| LEA FISHER | — |
| VALERIE HARDIN JEWETT | — |
| ANN KAPLAN | — |
| KIMBERLY LOVE | — |
| COLLEEN MALONEY | — |
| KENDRA MARTELLO | — |
| CARA MOON | — |
| ANNE PRITCHETT | — |
| LORI REILLY | — |
| JENNIFER ROMANS | — |
| RICHARD SMITH | — |
| JAMES M SPEARS | — |
| MATTHEW L SULKALA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.